DDrare: Database of Drug Development for Rare Diseases

107. 若年性特発性関節炎［全身型若年性特発性関節炎（~2018.3）］
［臨床試験数：151，薬物数：75（DrugBank：13），標的遺伝子数：16，標的パスウェイ数：90］

Searched query = "Juvenile idiopathic arthritis", "Systemic juvenile idiopathic arthritis", "Systemic-onset juvenile idiopathic arthritis", "JIA", "SJIA"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACTEMRA; ACZ885; ACZ885 150 mg (Canakinumab); ACZ885 Drug Substance; ACZ885G; ANAKINRA; APD421; Abatacept; Actemra; Actemra, MRA; Anakinra; Anakinra / kineret; BARICITINIB; Baricitinib; CANAKINUMAB; CCP-690-550-10; CP; CP-690,550-10; CSs; Canakinumab; Corticosteroids; EMAPALUMAB; Emapalumab; Fully human anti-interferon gamma monoclonal antibody; Heparin; IL-6 receptor inhibitor, recombinant humanized monoclonal antibody; ILARIS; ITF2357; Ilaris; In double-blind phase: treatment with tofacitinib; In open-label phase: treatment with tofacitinib; Interferon Gamma; KINERET*SC 7SIR 100MG 0,67ML; Kineret; Kineret® or anakinra; LY3009104; Ly3009104; MRA; MRA (Actemra); MRA (tocilizumab); MRA(Tocilizumab); MRA, Actemra; MTX; Methotrexate; NI-0501; NSAIDs; Non-steroidal anti-inflammatory drugs (NSAIDs); Null; Olumiant; Pneumo23; REGN88; RIL-1RA; RO4877533 (TCZ); Recombinant antihumanized anti-human monoclonal antibody directed against the IL-6R; Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class; Rilonacept; Rilonacept (IL-1 Trap); Ro 487-7533/F10-04; RoActemra; Roactemra; SAR153191; SAR153191 (REGN88); SARILUMAB; Sarilumab; Sarilumab SAR153191 (REGN88); TOCILIZUMAB; TOCILIZUMAB SC; TOFACITINIB CITRATE; Tocilizumab; Tocilizumab Roche; Tocilizumab SC; Tocilizumab [RoActemra/Actemra]; Tofacitinib; Tofacitinib citrate; Tofacitinibe citrate

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00144664 (ClinicalTrials.gov)	November 2004	2/9/2005	Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)	An Open-Label, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With pJIA	Systemic Juvenile Idiopathic Arthritis	Drug: MRA(Tocilizumab)	Chugai Pharmaceutical	NULL	Completed	2 Years	19 Years	Both	19	Phase 3	NULL
2	NCT00144612 (ClinicalTrials.gov)	July 2004	2/9/2005	Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)	An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP	Systemic Juvenile Idiopathic Arthritis	Drug: MRA(Tocilizumab)	Chugai Pharmaceutical	NULL	Completed	2 Years	19 Years	Both	60	Phase 3	NULL
3	NCT00144599 (ClinicalTrials.gov)	May 2004	2/9/2005	Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)	A Double-Blind, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With sJIA	Systemic Juvenile Idiopathic Arthritis	Drug: MRA(Tocilizumab);Drug: placebo	Chugai Pharmaceutical	NULL	Completed	2 Years	19 Years	Both	56	Phase 3	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00144664
(ClinicalTrials.gov)

November 2004

2/9/2005

Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)

An Open-Label, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With pJIA

Systemic Juvenile Idiopathic Arthritis

Drug: MRA(Tocilizumab)

Chugai Pharmaceutical

NULL

Completed

2 Years

19 Years

Both

Phase 3

NULL

NCT00144612
(ClinicalTrials.gov)

July 2004

2/9/2005

Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP

Systemic Juvenile Idiopathic Arthritis

Drug: MRA(Tocilizumab)

Chugai Pharmaceutical

NULL

Completed

2 Years

19 Years

Both

Phase 3

NULL

NCT00144599
(ClinicalTrials.gov)

May 2004

2/9/2005

Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

A Double-Blind, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With sJIA

Systemic Juvenile Idiopathic Arthritis

Drug: MRA(Tocilizumab);Drug: placebo

Chugai Pharmaceutical

NULL

Completed

2 Years

19 Years

Both

Phase 3

NULL